Abstract | BACKGROUND AND OBJECTIVES: GOAL OF THIS STUDY: STUDY DESIGN: Two diagnostic strategies were compared: 1) laboratory confirmation of chlamydia, and 2) presumptive diagnosis from the perspective of the healthcare system and the publicly funded clinic. RESULTS: From the healthcare perspective, the cost per case of pelvic inflammatory disease prevented with azithromycin ranges from a savings of $3,502 for laboratory confirmation to a cost of $792 for presumptive diagnosis. From the publicly funded clinic perspective, the cost per case of pelvic inflammatory disease prevented ranges from $709 for lab-confirmed diagnosis to $3,969 for presumptive treatment. CONCLUSION: For the healthcare system, azithromycin is a cost-effective alternative to doxycycline. However, the cost of azithromycin must decrease markedly for it to be less costly to the publicly funded clinic.
|
Authors | A C Haddix, S D Hillis, W J Kassler |
Journal | Sexually transmitted diseases
(Sex Transm Dis)
1995 Sep-Oct
Vol. 22
Issue 5
Pg. 274-80
ISSN: 0148-5717 [Print] United States |
PMID | 7502180
(Publication Type: Journal Article)
|
Chemical References |
- Anti-Bacterial Agents
- Azithromycin
|
Topics |
- Anti-Bacterial Agents
(economics, therapeutic use)
- Azithromycin
(economics, therapeutic use)
- Chlamydia Infections
(complications, drug therapy, economics)
- Chlamydia trachomatis
- Cohort Studies
- Cost-Benefit Analysis
- Female
- Humans
- Pelvic Inflammatory Disease
(economics, etiology, prevention & control)
|